City
Epaper

AstraZeneca's Fasenra gets DCGI nod for asthma treatment

By IANS | Updated: December 22, 2020 17:35 IST

Bengaluru, Dec 22 AstraZeneca India on Tuesday said it has received marketing authorisation from the Drugs Controller General ...

Open in App

Bengaluru, Dec 22 AstraZeneca India on Tuesday said it has received marketing authorisation from the Drugs Controller General of India (DCGI) for use of Fasenra for the management of patients with severe asthma.

Fasenra is not an inhaler or a steroid and is administered once in eight weeks under the skin via injection as maintenance therapy.

It is an add-on maintenance treatment for patients with severe eosinophilic asthma.

It is designed to target cells in the body called eosinophils, which are a key cause of the eosinophilic subtype of asthma.

Studies have also shown that patients on Fasenra could reduce their oral steroid intake significantly, thereby reducing the potential steroid-related side-effects.

The marketing authorisation from DCGI paves the way for the launch of Fasenra in India subject to other requisite regulatory approvals, AstraZeneca India said.

"AstraZeneca has always been at the forefront of innovative solutions for non-communicable diseases. Despite currently available therapies, a significant unmet need for effective management of severe asthma continues to exist globally as well as in India," Gagandeep Singh Bedi, Managing Director, AstraZeneca India, said in a statement.

"The regulatory approval of Fasenra in India will provide better medicine for the management of eosinophilic asthma and support patients to attain a better quality of life".

Asthma is a common, heterogeneous, chronic inflammatory disease of the airways that affects people of all ages and imposes a substantial burden on patients, their families, and the community.

It causes respiratory symptoms that are interspersed with attacks of breathlessness, which may require urgent health care and may result in emergency admission in hospital or sometimes be fatal.

The burden of asthma is immense as it causes limitations in daily activities, loss of school and work days, lung function impairment, reduced quality of life, and an adverse socioeconomic burden.

( With inputs from IANS )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

NationalDelhi’s Radisson Blu Hotel Catches Fire at Midnight as Sauna Room Engulfed in Flames (Watch Video)

MaharashtraMaharashtra: Minor Dies of Electric Shock After Touching AC Wire in Nallasopara Society

International"Peace, stability across Taiwan Strait important for international community": Japan's Foreign Minister

International11 Chinese aircraft, 7 naval vessels, 1 ship detected near Taiwan

InternationalSpain issues red alert for heavy rain in Catalonia

Health Realted Stories

HealthStudy reveals hidden heart risks in women with Type 2 Diabetes

HealthSugar & oil boards in govt offices, schools ‘excellent step’ for healthy India: Experts

HealthAIIA’s national seminar to explore trends in Ayurvedic surgical practices

HealthIIT Delhi launches MRI research facility to foster innovation in medical imaging

HealthWHO acknowledges India’s efforts in integrating AI in traditional medicine, Ayush